# Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

Study · id `cardio:ct-nct07667517` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07667517](<https://clinicaltrials.gov/study/NCT07667517>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07667517

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 148 participants.

## Technical summary

Registry record NCT07667517. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 148 participants (planned count; ClinicalTrials.gov record NCT07667517, source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07667517, source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT07667517, source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07667517, source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07667517, source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07667517-2026-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
- Condition: Albuminuria
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Finerenone (BAY 94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: First Affiliated Hospital of Zhejiang University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Zhejiang University (`cardio:org-first-affiliated-hospital-of-zhejiang-university`)

## Provenance

Content hash: 5f17928fa172a5503493d9ff73743b759071d1cc9a19cd43b7274ebb88e24b10
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
